HOME >> BIOLOGY >> NEWS
Targeted immunotherapy eradicates cancer in mice

NEW YORK, February 9, 2003 Researchers have developed a novel approach to genetically instruct human immune cells to recognize and kill cancer cells in a mouse model. The investigators plan to ultimately apply this strategy in a clinical trial setting for patients with certain forms of leukemias and lymphomas.

Scientists at Memorial Sloan-Kettering Cancer Center (MSKCC) genetically engineered an antigen receptor, introduced it into cultured human T cells, and infused the T cells in mice that bear widespread tumor cells. The modified T cells, now able to recognize the targeted antigen present on the tumor cells, eradicated the cancer.

The research will be published in the March 2003 issue of Nature Medicine and will be available on the journal's Web site on February 10. It is the first time that adoptive immunotherapy with engineered human T cells has demonstrated in vivo efficacy in mice.

"Our findings represent a step forward in the field of adoptive T cell therapy," said senior author Michel Sadelain, MD, PhD, Head of the Gene Transfer and Gene Expression Laboratory and Co-Director of the Gene Transfer and Somatic Cell Engineering Laboratory at MSKCC. "Our studies aim to better understand the biological needs of T cells that are targeted to tumors and may potentially be applied to a variety of cancers in the foreseeable future."

Earlier experiments have shown that genetically modified human T cells could kill tumor cells in vitro, but the cells could not successfully carry out other immunological responses such as maintaining cell division, and would die prematurely when they were infused into the body of a mouse. In this study, researchers may have overcome some of these limitations by designing a method whereby human T cells, genetically altered to recognize certain blood cancers, multiply in such a manner that they retain the ability to eliminate human tumors in vivo in mice.

Investigators g
'"/>

Contact: Esther Carver
mediastaff@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
9-Feb-2003


Page: 1 2

Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. Targeted therapy for lung cancer patients shows promise in extending lives
3. Targeted radiation to liver tumors spares tissue, improves quality of life
4. Targeted Genetics presents data on arthritis gene therapy
5. Targeted genetics presents promising data from cystic fibrosis clinical trial
6. Targeted Genetics presents clinical data on E1A cancer gene therapy
7. Targeted Genetics presents advances in systemic gene delivery technology
8. Targeted Genetics presents advances in synthetic gene delivery technologies
9. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
10. Fred Hutchinson Cancer Research Center And Targeted Genetics Announces Issuance Of Braod Patent Covering Antigen-Specific T Cell Expansion
11. Marine Snail Toxin Targeted At African Toad Eggs Reveals Novel Impact On The Regulation Of Serotonin

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/25/2018)... ... December 24, 2018 , ... Researchers at the ... a new use for a long-standing computational concept known as “blacklisting,” which is ... and messages. Using blacklisting as a filter to single out genetic variations in ...
(Date:12/19/2018)... ... December 19, 2018 , ... NDA Partners Chairman Carl Peck, MD, announced ... the FDA Center for Devices and Radiological Health (CDRH), has been appointed a Partner ... since 2015, and she has more than 25 years of regulatory experience. In addition ...
(Date:12/18/2018)... , ... December 18, 2018 , ... ... effectively incorporated artificial intelligence into client marketing. The technology has been effective at ... R3 Stem Cell has been working with clients nationwide on patient acquisition marketing ...
Breaking Biology News(10 mins):
(Date:1/15/2019)... ... ... the U.S. Congress designating January as Cervical Health Awareness Month , myLAB ... help reduce the risk of Cervical Cancer. , Cervical cancer is a slow-growing ... most common STD and an STI that almost half of all American adults have. ...
(Date:1/10/2019)... ... ... VGI Medical was founded in 2007 based on an invention developed by ... including VerteLoc, CerLoc, SiJoin and VerteLP. The VerteLoc and CerLoc systems are specifically designed ... design to limit motion of the affected spinal segment. Applying the principles of this ...
(Date:1/4/2019)... ... 01, 2019 , ... uBiome, the leader in microbial genomics, ... Meeting January 22-25, 2019 held in Davos-Klosters, Switzerland following their selection as a ... Meeting brings together leaders of global society–the heads and members of more than ...
(Date:12/19/2018)... ... 2018 , ... RURO, Inc., a leading provider of information ... The new release enhances the latest version of Limfinity®, RURO’s software framework, and ... , Validation protocols, and their execution, are critical for software systems scrutinized by ...
Breaking Biology Technology:
Cached News: